Literature DB >> 22922596

Stent choice and the hidden consequences of cost savings.

Matthew A Cavender1, Stephen G Ellis.   

Abstract

Amin and colleagues have attempted to estimate the cost savings to the US health-care system if drug-eluting coronary stents were more selectively used in patients at low risk of restenosis. Their results and conclusions raise statistical, societal, and ethical issues that need to be considered before this approach should be widely embraced.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22922596     DOI： 10.1038/nrcardio.2012.124

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  10 in total

1.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

Authors:  Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting
Journal:  J Am Coll Cardiol       Date:  2011-11-07       Impact factor: 24.094

2.  Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice.

Authors:  Amit P Amin; John A Spertus; David J Cohen; Adnan Chhatriwalla; Kevin F Kennedy; Katherine Vilain; Adam C Salisbury; Lakshmi Venkitachalam; Sue Min Lai; Laura Mauri; Sharon-Lise T Normand; John S Rumsfeld; John C Messenger; Robert W Yeh
Journal:  Arch Intern Med       Date:  2012-08-13

3.  Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies.

Authors:  Ajay J Kirtane; Anuj Gupta; Srinivas Iyengar; Jeffrey W Moses; Martin B Leon; Robert Applegate; Bruce Brodie; Edward Hannan; Kishore Harjai; Lisette Okkels Jensen; Seung-Jung Park; Raphael Perry; Michael Racz; Francesco Saia; Jack V Tu; Ron Waksman; Alexandra J Lansky; Roxana Mehran; Gregg W Stone
Journal:  Circulation       Date:  2009-06-15       Impact factor: 29.690

4.  Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention.

Authors:  Robert W Yeh; Sharon-Lise T Normand; Robert E Wolf; Philip G Jones; Kalon K L Ho; David J Cohen; Donald E Cutlip; Laura Mauri; Aaron D Kugelmass; Amit P Amin; John A Spertus
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

5.  Cost-effectiveness of drug-eluting stents versus bare metal stents in clinical practice.

Authors:  Pascha E Schafer; Matthew T Sacrinty; David J Cohen; Michael A Kutcher; Sanjay K Gandhi; Renato M Santos; William C Little; Robert J Applegate
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-06-21

6.  Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization.

Authors:  Stephen G Ellis; Christopher T Bajzer; Deepak L Bhatt; Sorin J Brener; Patrick L Whitlow; A Michael Lincoff; David J Moliterno; Russell E Raymond; E Murat Tuzcu; Irving Franco; Sandra Dushman-Ellis; Katherine J Lander; Jakob P Schneider; Eric J Topol
Journal:  Catheter Cardiovasc Interv       Date:  2004-10       Impact factor: 2.692

7.  Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.

Authors:  David J Cohen; Ameet Bakhai; Chunxue Shi; Louise Githiora; Tara Lavelle; Ronna H Berezin; Martin B Leon; Jeffrey W Moses; Joseph P Carrozza; James P Zidar; Richard E Kuntz
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

8.  Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.

Authors:  David R Holmes; Martin B Leon; Jeffrey W Moses; Jeffrey J Popma; Donald Cutlip; Peter J Fitzgerald; Charles Brown; Tim Fischell; Shing Chiu Wong; Mark Midei; David Snead; Richard E Kuntz
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

9.  Effectiveness and safety of drug-eluting stents in Ontario.

Authors:  Jack V Tu; James Bowen; Maria Chiu; Dennis T Ko; Peter C Austin; Yaohua He; Robert Hopkins; Jean-Eric Tarride; Gord Blackhouse; Charles Lazzam; Eric A Cohen; Ron Goeree
Journal:  N Engl J Med       Date:  2007-10-04       Impact factor: 91.245

10.  Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials.

Authors:  Donald E Cutlip; Manish S Chauhan; Donald S Baim; Kalon K L Ho; Jeffrey J Popma; Joseph P Carrozza; David J Cohen; Richard E Kuntz
Journal:  J Am Coll Cardiol       Date:  2002-12-18       Impact factor: 24.094
  10 in total
  1 in total

1.  Stratification of coronary artery disease patients for revascularization procedure based on estimating adverse effects.

Authors:  Sebastian Pölsterl; Maneesh Singh; Amin Katouzian; Nassir Navab; Adnan Kastrati; Lance Ladic; Ali Kamen
Journal:  BMC Med Inform Decis Mak       Date:  2015-02-14       Impact factor: 2.796
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.